Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
29.73
+0.29 (0.99%)
At close: Mar 9, 2026, 4:00 PM EDT
29.73
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:02 PM EDT
Enliven Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 33.8 | 23.78 | 17.66 | 7.77 | 4.29 | |
| Research & Development | 85.86 | 80.78 | 64.57 | 31.02 | 20.47 | |
| Operating Expenses | 119.66 | 104.55 | 82.23 | 38.79 | 24.76 | |
| Operating Income | -119.66 | -104.55 | -82.23 | -38.79 | -24.76 | |
| Interest & Investment Income | 16.01 | 14.89 | 11.97 | 1.13 | 0.02 | |
| Other Non Operating Income (Expenses) | -0.05 | -0 | -0.02 | - | - | |
| EBT Excluding Unusual Items | -103.69 | -89.67 | -70.28 | -37.66 | -24.74 | |
| Merger & Restructuring Charges | - | - | -1.3 | - | - | |
| Other Unusual Items | - | 0.87 | - | - | - | |
| Pretax Income | -103.69 | -88.79 | -71.58 | -37.66 | -24.74 | |
| Income Tax Expense | - | 0.23 | - | - | - | |
| Net Income | -103.69 | -89.02 | -71.58 | -37.66 | -24.74 | |
| Net Income to Common | -103.69 | -89.02 | -71.58 | -37.66 | -24.74 | |
| Shares Outstanding (Basic) | 57 | 47 | 36 | 3 | 8 | |
| Shares Outstanding (Diluted) | 57 | 47 | 36 | 3 | 8 | |
| Shares Change (YoY) | 20.38% | 32.43% | 1037.74% | -60.02% | 56.70% | |
| EPS (Basic) | -1.83 | -1.89 | -2.01 | -12.05 | -3.17 | |
| EPS (Diluted) | -1.83 | -1.89 | -2.01 | -12.05 | -3.17 | |
| Free Cash Flow | -70.46 | -73.24 | -61.42 | -32.69 | -19.33 | |
| Free Cash Flow Per Share | -1.24 | -1.56 | -1.73 | -10.46 | -2.47 | |
| EBITDA | -119.4 | -104.24 | -81.93 | -38.58 | -24.65 | |
| D&A For EBITDA | 0.26 | 0.32 | 0.3 | 0.22 | 0.12 | |
| EBIT | -119.66 | -104.55 | -82.23 | -38.79 | -24.76 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.